NRAS and colorectal cancer: During the NCI-MATCH trial (NCT02465060) investigating the use of the MEK inhibitor Binimetinib, a more favourable response was seen in NRAS-Q61-mutant colorectal cancer patients compared to those with NRAS-G12 or G13 mutations, with a median overall survival (mOS) of 15 months versus 5.1 (Cleary et al., 2021).